State of New Jersey Common Pension Fund D Sells 1,793 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of New Jersey Common Pension Fund D decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 1.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 130,162 shares of the medical equipment provider’s stock after selling 1,793 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Hologic were worth $9,300,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Nordea Investment Management AB increased its stake in Hologic by 4.5% in the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after acquiring an additional 69,494 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Hologic in the 4th quarter worth approximately $1,057,000. Pathstone Family Office LLC boosted its holdings in shares of Hologic by 96.0% in the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after purchasing an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board boosted its holdings in shares of Hologic by 186.7% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HOLX. UBS Group lifted their target price on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Hologic presently has an average rating of “Hold” and an average target price of $87.00.

Hologic Trading Down 1.3 %

HOLX traded down $1.00 during trading hours on Thursday, reaching $75.71. 1,190,936 shares of the company’s stock traded hands, compared to its average volume of 1,779,627. The firm has a 50-day moving average price of $75.95 and a 200 day moving average price of $72.72. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $17.77 billion, a PE ratio of 36.36, a PEG ratio of 2.61 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. During the same period in the prior year, the business earned $1.07 EPS. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. As a group, sell-side analysts predict that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.